Verastem Inc. (VSTM) and Arvinas Holding Company LLC (NASDAQ:ARVN) Comparing side by side

Verastem Inc. (NASDAQ:VSTM) and Arvinas Holding Company LLC (NASDAQ:ARVN) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verastem Inc. 26.72M 9.40 72.43M -1.44 0.00
Arvinas Holding Company LLC 13.46M 38.80 233.06M -7.47 0.00

Table 1 highlights Verastem Inc. and Arvinas Holding Company LLC’s top-line revenue, earnings per share and valuation.


Table 2 provides us Verastem Inc. and Arvinas Holding Company LLC’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Verastem Inc. -271.07% -95.9% -61.7%
Arvinas Holding Company LLC -1,731.50% 0% 0%


Verastem Inc. has a Current Ratio of 3 and a Quick Ratio of 3. Competitively, Arvinas Holding Company LLC’s Current Ratio is 4.8 and has 4.8 Quick Ratio. Arvinas Holding Company LLC’s better ability to pay short and long-term obligations than Verastem Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Verastem Inc. and Arvinas Holding Company LLC.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Verastem Inc. 0 0 3 3.00
Arvinas Holding Company LLC 0 0 0 0.00

Verastem Inc.’s upside potential is 194.12% at a $10 average target price.

Insider and Institutional Ownership

The shares of both Verastem Inc. and Arvinas Holding Company LLC are owned by institutional investors at 61.5% and 56.5% respectively. About 0.6% of Verastem Inc.’s share are owned by insiders. On the other hand, insiders owned about 13.1% of Arvinas Holding Company LLC’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Verastem Inc. -6.71% -6.71% -39.88% -68.31% 0.33% -8.93%
Arvinas Holding Company LLC -2.4% 5.23% 1.38% 0% 0% 42.57%

For the past year Verastem Inc. has -8.93% weaker performance while Arvinas Holding Company LLC has 42.57% stronger performance.


Verastem Inc. beats on 6 of the 11 factors Arvinas Holding Company LLC.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The companyÂ’s defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The companyÂ’s duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.